Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
Top Cited Papers
Open Access
- 1 January 2020
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 8 (1), e000331
- https://doi.org/10.1136/jitc-2019-000331
Abstract
Background Uveal melanoma (UM) is the most common intraocular malignancy in adults. In contrast to cutaneous melanoma (CM), there is no standard therapy, and the efficacy and safety of dual checkpoint blockade with nivolumab and ipilimumab is not well defined. Methods We conducted a retrospective analysis of patients with metastatic UM (mUM) who received treatment with ipilimumab plus nivolumab across 14 academic medical centers. Toxicity was graded using National Cancer Institute Common Terminology Criteria for Adverse Events V.5.0. Progression-free survival (PFS) and overall survival (OS) were calculated using Kaplan-Meier methodology. Results 89 eligible patients were identified. 45% had received prior therapy, which included liver directed therapy (29%), immunotherapy (21%), targeted therapy (10%) and radiation (16%). Patients received a median 3 cycles of ipilimumab plus nivolumab. The median follow-up time was 9.2 months. Overall response rate was 11.6%. One patient achieved complete response (1%), 9 patients had partial response (10%), 21 patients had stable disease (24%) and 55 patients had progressive disease (62%). Median OS from treatment initiation was 15 months and median PFS was 2.7 months. Overall, 82 (92%) of patients discontinued treatment, 34 due to toxicity and 27 due to progressive disease. Common immune-related adverse events were colitis/diarrhea (32%), fatigue (23%), rash (21%) and transaminitis (21%). Conclusions Dual checkpoint inhibition yielded higher response rates than previous reports of single-agent immunotherapy in patients with mUM, but the efficacy is lower than in metastatic CM. The median OS of 15 months suggests that the rate of clinical benefit may be larger than the modest response rate.Keywords
This publication has 42 references indexed in Scilit:
- Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysisMelanoma Research, 2019
- Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma studyAnnals Of Oncology, 2019
- Immune checkpoint blockade for unresectable or metastatic uveal melanoma: A systematic reviewCancer Treatment Reviews, 2017
- Phase II multicenter, single arm, open label study of nivolumab (NIVO) in combination with ipilimumab (IPI) as first line in adult patients (pts) with metastatic uveal melanoma (MUM): GEM1402 NCT02626962.Journal of Clinical Oncology, 2017
- Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First MetastasisThe Oncologist, 2016
- Phase II Trial of Sorafenib in Combination with Carboplatin and Paclitaxel in Patients with Metastatic Uveal Melanoma: SWOG S0512PLOS ONE, 2012
- Uveal Melanoma: Trends in Incidence, Treatment, and SurvivalOphthalmology, 2011
- Development of Metastatic Disease After Enrollment in the COMS Trials for Treatment of Choroidal MelanomaAmerican Journal of Ophthalmology, 2005
- Screening for Metastasis From Choroidal Melanoma: The Collaborative Ocular Melanoma Study Group Report 23Journal of Clinical Oncology, 2004
- The National Cancer Data Base report on cutaneous and noncutaneous melanomaCancer, 1998